SCHEMBL5565359

SCHEMBL5565359

CN[C@@H](C(C)C)[C@@H](CC(=O)OC(C)(C)C)OC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.51
CA2 P00918 2/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
CA12 O43570 2/20 0.33
CA14 Q9ULX7 2/20 0.33
DGAT1 O75907 1/20 0.32
MMP1 P03956 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
MLYCD O95822 7/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14350548 1.00 CYP2D6 (0.51) CYP2D6CA2CA1CA7HDAC3
Hydrochloric Acid SCHEMBL5565353 0.98 CYP2D6 (0.50) CYP2D6CA2CA1CA7HDAC3
SCHEMBL903397 0.86 CYP2D6 (0.41) CYP2D6CA2HDAC3HDAC1HDAC2
SCHEMBL21065977 0.86 CYP2D6 (0.41) CYP2D6CA2HDAC3HDAC1HDAC2
SCHEMBL25721686 0.86 CYP2D6 (0.41) CYP2D6CA2HDAC3HDAC1HDAC2
SCHEMBL14350539 0.86 CYP2D6 (0.41) CYP2D6CA2HDAC3HDAC1HDAC2
Hydrochloric Acid SCHEMBL21066070 0.85 CYP2D6 (0.40) CYP2D6CA2HDAC3HDAC1HDAC2
Hydrochloric Acid SCHEMBL5656221 0.85 CYP2D6 (0.40) CYP2D6CA2HDAC3HDAC1HDAC2
SCHEMBL14350559 0.83 CYP2D6 (0.43) CYP2D6CA2CA1CA7HDAC3
SCHEMBL5559800 0.83 CYP2D6 (0.43) CYP2D6CA2CA1CA7HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312343-B2 N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 HOFFMANN-LA ROCHE INC. (US) 2007-12-25 US disclosed
EP-1756038-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
WO-2005118525-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2005-12-15 WO disclosed
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 US disclosed
US-5939527-A SYNTHETIC OLIGOPEPTIDE WITH BIOLOGICAL ACTIVITY OF DOLASTATIN FROM SEA HARE BASF AKTIENGESELLSCHAFT (DE) 1999-08-17 US disclosed
US-5741892-A Pentapeptides as antitumor agents BASF AKTIENGESELLSCHAFT (DE) 1998-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters ALDH7A1, BCAT1, BCAT2 CYP2D6 285/4885CA2 1831/4885CA1 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.